Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

Documenti analoghi

• Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single‐Center Retrospective Analysis
  di: Jason S. Gilbert, et al.
  Pubblicazione: (2025)
• Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
  di: Tapan M. Kadia, et al.
  Pubblicazione: (2026)
• Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia
  di: Georgio Medawar, et al.
  Pubblicazione: (2026)
• Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies
  di: Keith W. Pratz, et al.
  Pubblicazione: (2026)
• Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML ‐ M4 and AML ‐ M5 , Treated With Venetoclax Plus Azacitidine
  di: Marina Konopleva, et al.
  Pubblicazione: (2026)